Johnson & Johnson (JNJ)’s Incivo won the backing of the U.K.’s health-cost regulator in a draft recommendation for the treatment of hepatitis C. The medicine, also known as telaprevir or Incivek, is a cost-effective option for chronically infected hepatitis C patients when used with older drugs peginterferon alfa and ribavirin, the National Institute for Health and Clinical Excellence said today in a statement. The agency advises the state-run National Health Service on which products represent value for money.
